ADOCIA SAS (ADOC.PA) Stock Price, Quote, News and Overview
EPA:ADOC - Euronext Paris - Matif - FR0011184241 - Common Stock - Currency: EUR
ADOC.PA Quote, Performance and Key Statistics
EPA:ADOC (5/9/2025, 12:42:10 PM)
4.065
+0.11 (+2.65%)
The current stock price of ADOC.PA is 4.065 EUR. In the past month the price increased by 21.66%. In the past year, price decreased by -54.11%.
ADOC.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1ABBV.MI | ABBVIE INC | 18.28 | 294.00B | ||
| 4AB.DE | ABBVIE INC | 18.06 | 290.47B | ||
| AMG.DE | AMGEN INC | 13.13 | 129.73B | ||
| GIS.DE | GILEAD SCIENCES INC | 12.72 | 108.48B | ||
| 1GILD.MI | GILEAD SCIENCES INC | 12.71 | 108.39B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | 1453.46 | 97.15B | ||
| ARGX.BR | ARGENX SE | 105.35 | 30.49B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 20.35B | ||
| IDP.DE | BIOGEN INC | 7.5 | 15.39B | ||
| 0QF.DE | MODERNA INC | N/A | 8.44B | ||
| 1MRNA.MI | MODERNA INC | N/A | 8.14B | ||
| BIO.DE | BIOTEST AG | 65.54 | 1.69B |
Related stock screener links
About ADOC.PA
Company Profile
Adocia SA is a clinical-stage biotechnology company, which engages in the development of medicines from already-approved therapeutic proteins and peptides. The company is headquartered in Lyon, Auvergne-Rhone-Alpes. The company went IPO on 2012-02-20. The firm specializes in the development of formulations of already-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary technological platform BioChaperone is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. The Company’s clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two formulations of insulin analog lispro (BioChaperone Lispro U100 and U200), a combination of basal insulin glargine and insulin lispro (BioChaperone Combo), and a combination of prandial insulin with amylin analog pramlintide: M1Pram. Its preclinical pipeline includes three products BioChaperone LisPram, BioChaperone Glargine GLP-1 and BioChaperone Glucagon GLP1.
Company Info
ADOCIA SAS
115 avenue Lacassagne
Lyon AUVERGNE-RHONE-ALPES FR
Employees: 76
Phone: 33472610610
ADOCIA SAS / ADOC.PA FAQ
What is the stock price of ADOCIA SAS today?
The current stock price of ADOC.PA is 4.065 EUR. The price increased by 2.65% in the last trading session.
What is the ticker symbol for ADOCIA SAS stock?
The exchange symbol of ADOCIA SAS is ADOC and it is listed on the Euronext Paris - Matif exchange.
On which exchange is ADOC.PA stock listed?
ADOC.PA stock is listed on the Euronext Paris - Matif exchange.
What is the price forecast or stock price prediction for ADOCIA SAS stock?
7 analysts have analysed ADOC.PA and the average price target is 9.33 EUR. This implies a price increase of 129.59% is expected in the next year compared to the current price of 4.065. Check the ADOCIA SAS stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ADOCIA SAS worth?
ADOCIA SAS (ADOC.PA) has a market capitalization of 73.50M EUR. This makes ADOC.PA a Micro Cap stock.
How many employees does ADOCIA SAS have?
ADOCIA SAS (ADOC.PA) currently has 76 employees.
What are the support and resistance levels for ADOCIA SAS (ADOC.PA) stock?
ADOCIA SAS (ADOC.PA) has a support level at 3.95 and a resistance level at 4.04. Check the full technical report for a detailed analysis of ADOC.PA support and resistance levels.
Is ADOCIA SAS (ADOC.PA) expected to grow?
The Revenue of ADOCIA SAS (ADOC.PA) is expected to grow by 122.22% in the next year. Check the estimates tab for more information on the ADOC.PA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ADOCIA SAS (ADOC.PA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ADOC.PA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ADOC.PA, evaluating the profitability, health, valuation and growth aspects
- ADOCIA SAS (ADOC.PA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ADOCIA SAS (ADOC.PA) Sales and EPS estimates to see what analysts future expectations are.
- ADOCIA SAS (ADOC.PA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ADOCIA SAS (ADOC.PA) Insider and Institutional Ownership to learn about the owners and their transactions.
- ADOCIA SAS (ADOC.PA) Stock Chart to make your own analysis
- ADOCIA SAS (ADOC.PA) Latest news and press-releases to stay up to date.
Does ADOCIA SAS (ADOC.PA) stock pay dividends?
ADOC.PA does not pay a dividend.
When does ADOCIA SAS (ADOC.PA) report earnings?
ADOCIA SAS (ADOC.PA) will report earnings on 2025-05-14.
What is the Price/Earnings (PE) ratio of ADOCIA SAS (ADOC.PA)?
ADOCIA SAS (ADOC.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.53).
ADOC.PA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ADOC.PA. When comparing the yearly performance of all stocks, ADOC.PA is a bad performer in the overall market: 96.83% of all stocks are doing better.
ADOC.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ADOC.PA. Both the profitability and financial health of ADOC.PA have multiple concerns.
ADOC.PA Financial Highlights
Over the last trailing twelve months ADOC.PA reported a non-GAAP Earnings per Share(EPS) of -1.53. The EPS increased by 35.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -87.56% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ADOC.PA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to ADOC.PA. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 140.65% and a revenue growth 122.22% for ADOC.PA